Phase 3
N=52
In Situ Comparison of the Remineralization Potential of Optimized Fluoride Dentifrice With Control Fluoride Dentifrice
Caries
Bottom Line
View on ClinicalTrials.gov: NCT06010732 ↗Enrolled (actual)
52
Serious AEs
1.3%
Results posted
Jun 2025
Primary outcome: Primary: Percent Surface Microhardness Recovery (%SMH Recovery) — 24.4; 51.6; 51.5 Percent Surface Microhardness Recovery — p=0.986
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- 0 ppm F (placebo, negative control) (Drug); 1100 ppm F as sodium fluoride (positive control) (Drug); 1100 ppm F as sodium fluoride Test Product (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Indiana University
- Primary completion
- Feb 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Surface Microhardness Recovery (%SMH Recovery) |
24.4; 51.6; 51.5 | 0.986 |
| SECONDARY Enamel Fluoride Uptake (µg F/cm2) |
1.99; 10.32; 11.45 | 0.230 |
| SECONDARY Percent Net Acid Resistance |
2.6; 34.3; 37.4 | 0.272 |
| SECONDARY Percentage Comparative Acid Resistance |
20.27; 16.40; 13.51 | 0.191 |
| SECONDARY Integrated Mineral Loss (∆Z) |
998; 703; 708 | 0.905 |
| SECONDARY Lesion Depth (µm) |
40.5; 31.2; 30.6 | 0.721 |
| SECONDARY Maximum Mineral Density at the Surface-zone (SZmax) |
59.26; 66.17; 65.61 | 0.647 |
Summary
The purpose of this study is to compare the remineralization potential of an optimized fluoride dentifrice to a control fluoride dentifrice in an in situ caries model.
Eligibility Criteria
Inclusion Criteria
- provide voluntary, written informed consent;
- be between 18 and 85 years old;
- understand and be willing, able and likely to comply with all study procedures and restrictions;
- be wearing a removable mandibular partial denture with sufficient room to accommodate two 4 mm round specimens in the buccal surface of two posterior denture teeth on the same side;
- be willing and capable of wearing their removable partial denture 24 hours a day for three (3), two-week treatment periods;
- be willing to allow study personnel to drill specimen sites in two denture teeth in the posterior section of one side of their lower partial denture, which may extend into the buccal flange area below the teeth;
- be in good medical and dental health with no active caries or periodontal disease; NOTE: subjects presenting at screening with caries may continue in the study if their carious lesions are restored prior to beginning treatment 1; and
- have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 mL/min; gum base stimulated whole saliva flow rate ≥ 0.8 mL/min).
Exclusion Criteria
- currently be pregnant, intending to become pregnant during the study period or breast feeding;
- currently have any medical condition that could be expected to interfere with the subject's safety during the study period;
- currently be taking antibiotics or have taken antibiotics in the two weeks prior to the beginning treatment 1;
- known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients;
- have participated in another clinical study or receipt of an investigational drug within 30 days of beginning treatment 1; or
- be taking fluoride supplements, required to use a fluoride mouthrinse or have received a professional fluoride treatment in the two weeks preceding specimen placement.
Data sourced from ClinicalTrials.gov (NCT06010732). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.